# Daliresp

NDC: 0310-0088
Generic name: roflumilast
Labeler / Manufacturer: AstraZeneca Pharmaceuticals LP
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET
Routes: ORAL
Marketing started: 20150701

FDA application: NDA022522

## Active ingredients

- ROFLUMILAST: 250 ug/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0310-0088"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0310-0088
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf